Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. [PDF]
Anguela XM, High KA.
europepmc +1 more source
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B. [PDF]
Vandewalle B +8 more
europepmc +1 more source
Protein S antibody as an adjunct therapy for hemophilia B. [PDF]
Wilson HP +11 more
europepmc +1 more source
Successful immunosuppressive drug-free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report. [PDF]
Palomo Bravo Á +4 more
europepmc +1 more source
Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.
Lee K +8 more
europepmc +1 more source
Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States. [PDF]
Wilson M +5 more
europepmc +1 more source
Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management. [PDF]
Benitez-Hidalgo O +6 more
europepmc +1 more source
Clinical analysis and quality of life survey of hemophilia B patients in the central and western regions of China. [PDF]
Wang W +13 more
europepmc +1 more source
[Chinese guidance for the clinical application of Adeno-associated virus vector-based gene therapy for hemophilia B (2025)]. [PDF]
Thrombosis and Hemostasis Group +3 more
europepmc +1 more source
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B. [PDF]
Pauly N +7 more
europepmc +1 more source

